Ann Polonskaia

632 total citations
11 papers, 447 citations indexed

About

Ann Polonskaia is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Ann Polonskaia has authored 11 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Hematology and 4 papers in Oncology. Recurrent topics in Ann Polonskaia's work include Multiple Myeloma Research and Treatments (4 papers), Protein Degradation and Inhibitors (4 papers) and Peptidase Inhibition and Analysis (3 papers). Ann Polonskaia is often cited by papers focused on Multiple Myeloma Research and Treatments (4 papers), Protein Degradation and Inhibitors (4 papers) and Peptidase Inhibition and Analysis (3 papers). Ann Polonskaia collaborates with scholars based in United States, Canada and United Kingdom. Ann Polonskaia's co-authors include Yemiliya Berman, Nino Mzhavia, Lakshmi A. Devi, Anjan Thakurta, Chad C. Bjorklund, Michael Amatangelo, Jian Kang, John E. Pintar, Fadi Towfic and Machi Furuta and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Journal of Neurochemistry.

In The Last Decade

Ann Polonskaia

10 papers receiving 437 citations

Peers

Ann Polonskaia

HEMAT

ONCOL

CMN

Mengtao Xiao China

Satoshi Yoshimura United States

Judith L. Scott Australia

Eunyee Kwak South Korea

Elena Beltrán Spain

Jane E. Wright United Kingdom

Sadanand Vodala United States

J Y Chang Switzerland

Yu-San Yang United States

Aliaksei Shymanets Germany

Mengtao Xiao China

Ann Polonskaia

411 ×1.2

82 ×0.6

HEMAT

49 ×0.4

ONCOL

11 ×0.2

CMN

34 ×0.7

Citations per year, relative to Ann Polonskaia Ann Polonskaia (= 1×) peers Mengtao Xiao

Countries citing papers authored by Ann Polonskaia

Since Specialization

Citations

This map shows the geographic impact of Ann Polonskaia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Polonskaia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Polonskaia more than expected).

Fields of papers citing papers by Ann Polonskaia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Polonskaia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Polonskaia. The network helps show where Ann Polonskaia may publish in the future.

Co-authorship network of co-authors of Ann Polonskaia

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Polonskaia. A scholar is included among the top collaborators of Ann Polonskaia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Polonskaia. Ann Polonskaia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Jeyaraju, Danny V., et al.. (2023). Fedratinib Overcomes Ruxolitinib Resistance through Inhibition of the Interferon Signaling Pathway. Blood. 142(Supplement 1). 1434–1434.

Gooding, Sarah, Naser Ansari‐Pour, Kübra Karagoz, et al.. (2022). Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma. Blood. 140(16). 1816–1821. 13 indexed citations

Jeyaraju, Danny V., Sheida Hayati, Ann Polonskaia, et al.. (2022). Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial. Blood. 140(Supplement 1). 3865–3867. 1 indexed citations

Ahsan, Aarif, Ann Polonskaia, Chad C. Bjorklund, et al.. (2021). Super-Enhancer Driven Regulation of CKS1B in Multiple Myeloma: Implications in Mediating Response to BET Inhibitor and Celmod Agent Combination. Blood. 138(Supplement 1). 2658–2658. 1 indexed citations

Bjorklund, Chad C., Jian Kang, Michael Amatangelo, et al.. (2019). Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 34(4). 1197–1201. 144 indexed citations

Amatangelo, Michael, et al.. (2018). Iberdomide (CC-220) Has Synergistic Anti-Tumor and Immunostimulatory Activity Against Multiple Myeloma in Combination with Both Bortezomib and Dexamethasone, or in Combination with Daratumumab in Vitro. Blood. 132(Supplement 1). 1935–1935. 24 indexed citations

Chen, Yi, Zhi Chen, Romyr Dominique, et al.. (2013). Pyrido[2,3-d]pyrimidines: Discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(24). 6610–6615. 48 indexed citations

Ewton, Daina Z., Jing Hu, Maria Vilenchik, et al.. (2011). Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells. Molecular Cancer Therapeutics. 10(11). 2104–2114. 56 indexed citations

Pikovskaya, Olga, Artem A. Serganov, Ann Polonskaia, Alexander Serganov, & Dinshaw J. Patel. (2009). Preparation and Crystallization of Riboswitch–Ligand Complexes. Methods in molecular biology. 540. 115–128. 31 indexed citations

10.

Berman, Yemiliya, Nino Mzhavia, Ann Polonskaia, & Lakshmi A. Devi. (2001). Impaired Prohormone Convertases in Cpe fat/Cpe fat Mice. Journal of Biological Chemistry. 276(2). 1466–1473. 54 indexed citations

11.

Berman, Yemiliya, Nino Mzhavia, Ann Polonskaia, et al.. (2000). Defective Prodynorphin Processing in Mice Lacking Prohormone Convertase PC2. Journal of Neurochemistry. 75(4). 1763–1770. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact